{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:59:53Z","timestamp":1794340793268,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity and type 2 diabetes are the primary drivers of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death worldwide. Injectable GLP-1 receptor agonists reduce major adverse cardiovascular events. Yet for many individuals, injection hesitancy remains a significant barrier to long-term adherence. Orforglipron is a novel once-daily oral non-peptide GLP-1 receptor agonist designed to provide comprehensive cardiometabolic risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRISMA-compliant systematic review and meta-analysis (PROSPERO CRD420251229397) of placebo-controlled phase 2 and phase 3 trials of orforglipron. Random-effects models were used to pool mean differences (MD) and risk ratios (RR) with 95% confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across four large trials, orforglipron produced dose-dependent, clinically meaningful improvements in major modifiable cardiovascular risk factor compared with placebo: body weight \u2212\u20096.08% (95% CI \u2212\u20097.68 to \u2212\u20094.47; up to \u2212\u20099.31% at higher doses), HbA1c \u2212\u20090.85% (95% CI \u2212\u20091.53 to \u2212\u20090.18; up to \u2212\u20091.36%), systolic blood pressure \u2212\u20094.32 mmHg (95% CI \u2212\u20095.61 to \u2212\u20093.03; up to \u2212\u20095.78 mmHg at 45\u00a0mg), LDL-cholesterol \u2212\u20094.14% (95% CI \u2212\u20096.38 to \u2212\u20091.91), triglycerides \u2212\u200910.90% (95% CI \u2212\u200914.36 to \u2212\u20097.43), VLDL-cholesterol \u2212\u200910.81% (95% CI \u2212\u200914.10 to \u2212\u20097.51), and HDL-cholesterol\u2009+\u20093.31% (95% CI\u2009+\u20091.66 to +\u20094.97). Notably, heterogeneity was very low to absent (I\u00b2 = 0%) for systolic blood pressure and all lipid outcomes. Gastrointestinal side effects were common but typical of the GLP-1 class (nausea RR 5.22, vomiting RR 3.24, eructation RR 6.80).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Orforglipron provides highly consistent reductions across the full spectrum of ASCVD risk factors, with effect sizes on lipids and blood pressure comparable to those linked to MACE reduction in trials of injectable GLP-1 receptor agonists. As a novel small-molecule GLP-1 agonist in its class, Orforglipron offers a transformative option for comprehensive cardiometabolic risk reduction and ASCVD prevention in patients with obesity and type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-025-00270-4","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:03:34Z","timestamp":1771542214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review"],"prefix":"10.1186","volume":"12","author":[{"given":"Adir","family":"Alper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyansh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishmum","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Faillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"270_CR1","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms25031882","volume":"25","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes Mellitus-An overview. Int J Mol Sci. 2024;25:1882.","journal-title":"Int J Mol Sci"},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","volume":"387","author":"Trends in adult","year":"2016","unstructured":"Trends in adult. body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19\u00b72 million participants. Lancet. 2016;387:1377\u201396.","journal-title":"Lancet"},{"key":"270_CR3","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"JD Stanaway","year":"2018","unstructured":"Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and National comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1923\u201394.","journal-title":"Lancet"},{"issue":"25","key":"270_CR4","first-page":"07428","volume":"S0735\u20131097","author":"GBD 2023 Cardiovascular Disease Collaborators","year":"2025","unstructured":"GBD 2023 Cardiovascular Disease Collaborators. Global, Regional, and National burden of cardiovascular diseases and risk factors in 204 countries and Territories, 1990\u20132023. J Am Coll Cardiol. 2025;S0735\u20131097(25):07428\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"270_CR5","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Ekhlaspour L, Gaglia JL, Hilliard ME, Johnson EL, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of care in Diabetes\u20142024. Diabetes Care. 2024;47:S158\u201378.","journal-title":"Diabetes Care"},{"key":"270_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/MED.0000000000000085","volume":"21","author":"KJ Strissel","year":"2014","unstructured":"Strissel KJ, Denis GV, Nikolajczyk BS. Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease. Curr Opin Endocrinol Diabetes Obes. 2014;21:330\u20138.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet"},{"key":"270_CR8","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab"},{"key":"270_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"270_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841\u201351.","journal-title":"N Engl J Med"},{"key":"270_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330.","journal-title":"Lancet"},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, K\u00f8ber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"270_CR13","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/PPA.S106821","volume":"10","author":"W Polonsky","year":"2016","unstructured":"Polonsky W, Henry R. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. PPA. 2016;10:1299\u2013307.","journal-title":"PPA"},{"key":"270_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40842-025-00245-5","volume":"11","author":"G Santulli","year":"2025","unstructured":"Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovasc Diabetol Endocrinol Rep. 2025;11:31.","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"270_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40262-023-01223-9","volume":"62","author":"M Van Hout","year":"2023","unstructured":"Van Hout M, Forte P, Jensen TB, Boschini C, B\u00e6kdal TA. Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: A randomised trial in healthy subjects. Clin Pharmacokinet. 2023;62:635\u201344.","journal-title":"Clin Pharmacokinet"},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jama.2025.14392","volume":"334","author":"MJ Gonzalez-Rellan","year":"2025","unstructured":"Gonzalez-Rellan MJ, Drucker DJ. New molecules and indications for GLP-1 medicines. JAMA. 2025;334:1231.","journal-title":"JAMA"},{"key":"270_CR17","doi-asserted-by":"publisher","first-page":"116632","DOI":"10.1016\/j.ejmech.2024.116632","volume":"275","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wu T, Wu Y, Peng Y, Wei X, Lu T, Jiao Y. Binding sites and design strategies for small molecule GLP-1R agonists. Eur J Med Chem. 2024;275:116632.","journal-title":"Eur J Med Chem"},{"key":"270_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","volume":"80","author":"X Zhang","year":"2020","unstructured":"Zhang X, Belousoff MJ, Zhao P, Kooistra AJ, Truong TT, Ang SY, Underwood CR, Egebjerg T, \u0160enel P, Stewart GD, et al. Differential GLP-1R binding and activation by peptide and Non-peptide agonists. Mol Cell. 2020;80:485\u2013e5007.","journal-title":"Mol Cell"},{"key":"270_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature22394","volume":"546","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, Tarrasch JT, Li S, Sun Kobilka T, Kobilka BK, et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature. 2017;546:248\u201353.","journal-title":"Nature"},{"key":"270_CR20","doi-asserted-by":"crossref","unstructured":"Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc. Natl. Acad. Sci. U.S.A. 2020;117:29959\u201329967.","DOI":"10.1073\/pnas.2014879117"},{"key":"270_CR21","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/dom.15184","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, Sloop KW, Benson C. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25:2634\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"270_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/dom.15372","volume":"26","author":"E Pratt","year":"2024","unstructured":"Pratt E. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2024;26:1137.","journal-title":"Diabetes Obes Metab"},{"key":"270_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, et al. Efficacy and safety of oral Orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402:472\u201383.","journal-title":"Lancet"},{"key":"270_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu W-S, Liu R, Li J, Fern\u00e1ndez Land\u00f3 L, Denning M, et al. Orforglipron, an oral Small-Molecule GLP-1 receptor Agonist, in early type 2 diabetes. N Engl J Med. 2025;393:1065\u201376.","journal-title":"N Engl J Med"},{"key":"270_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, et al. Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity. N Engl J Med. 2023;389:877\u201388.","journal-title":"N Engl J Med"},{"key":"270_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"270_CR27","doi-asserted-by":"crossref","unstructured":"Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;NEJMoa2511774.","DOI":"10.1056\/NEJMoa2511774"},{"key":"270_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","volume":"24","author":"S Wharton","year":"2025","unstructured":"Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025;24:240.","journal-title":"Cardiovasc Diabetol"},{"key":"270_CR29","doi-asserted-by":"publisher","first-page":"e70134","DOI":"10.1002\/edm2.70134","volume":"8","author":"RK Pandey","year":"2025","unstructured":"Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA, Amir AB, Ahmed S, Safiullah M, Bhatti MI, et al. Efficacy and safety of Orforglipron in obese adults with or without diabetes: A systematic review and Meta-Analysis. Endocrino Diabet Metabol. 2025;8:e70134.","journal-title":"Endocrino Diabet Metabol"},{"key":"270_CR30","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71.","DOI":"10.1136\/bmj.n71"},{"key":"270_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"270_CR32","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"270_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"270_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"270_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187\u201394.","journal-title":"Curr Obes Rep"},{"key":"270_CR36","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"270_CR37","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, Pinho-Gomes A-C, Woodward M, Adler A, Agodoa L, et al. Pharmacological blood pressure Lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625\u201336.","journal-title":"Lancet"},{"key":"270_CR38","doi-asserted-by":"publisher","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnell CJ et al. 2013 ACC\/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation [Internet]. 2014 [cited 2025 Nov 6];129. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/01.cir.0000437741.48606.98","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"270_CR39","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2014.2630","volume":"311","author":"P Muntner","year":"2014","unstructured":"Muntner P, Colantonio LD, Cushman M, Goff DC, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406.","journal-title":"JAMA"},{"key":"270_CR40","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","volume":"64","author":"KN Karmali","year":"2014","unstructured":"Karmali KN, Goff DC, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959\u201368.","journal-title":"J Am Coll Cardiol"},{"key":"270_CR41","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"270_CR42","doi-asserted-by":"publisher","first-page":"107991","DOI":"10.4330\/wjc.v17.i8.107991","volume":"17","author":"S Bhat","year":"2025","unstructured":"Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM. Efficacy and safety of incretin co-agonists: transformative advances in cardiometabolic healthcare. World J Cardiol. 2025;17:107991.","journal-title":"World J Cardiol"},{"key":"270_CR43","doi-asserted-by":"publisher","first-page":"133683","DOI":"10.1016\/j.ijcard.2025.133683","volume":"440","author":"TG Rebelo","year":"2025","unstructured":"Rebelo TG, De Araujo Paysano MLB, Matheus GTFU, Ribeiro DM, Said TB, Kelly FA. Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis. Int J Cardiol. 2025;440:133683.","journal-title":"Int J Cardiol"},{"key":"270_CR44","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang C-Z, Wan J-Y, Yuan C-S. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"key":"270_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, Liu B, Cui X, Brown K. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"270_CR46","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1111\/dom.16549","volume":"27","author":"N Sattar","year":"2025","unstructured":"Sattar N, Garc\u00eda-P\u00e9rez L, Rodr\u00edguez A, Kapoor R, Stefanski A, Hankosky ER. Tirzepatide and cardiometabolic parameters in obesity: summary of current evidence. Diabetes Obes Metabolism. 2025;27:5386\u201392.","journal-title":"Diabetes Obes Metabolism"},{"key":"270_CR47","doi-asserted-by":"publisher","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, Chen Y, Zhou X, Liu S, Yu J. GLP-1RAs caused Gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol. 2023;14:1149328.","journal-title":"Front Endocrinol"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00270-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:02:11Z","timestamp":1781650931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00270-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00270-4","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}